echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Pfizer abrocitinib and Xeljanz review delayed by FDA for 3 months

    Pfizer abrocitinib and Xeljanz review delayed by FDA for 3 months

    • Last Update: 2021-04-18
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Compilenewborn

    On April 7, Pfizer announced that the US FDA has extended the priority review period for the new drug application (NDA) for the oral anti-inflammatory drug abrocitinib.


    In addition, the FDA has extended the review period of the supplementary new drug application (sNDA) for the oral anti-inflammatory drug Xeljanz/Xeljanz XR (tofacitinib, tofacitinib) for the treatment of adult patients with active ankylosing spondylitis (AS) by 3 months.


    Abrocitinib is an oral small molecule that selectively inhibits Janus kinase 1 (JAK1).


    Xeljanz was approved in 2012 and is the first JAK inhibitor on the market.


    In the announcement, Pfizer did not disclose the reasons for the FDA's postponement of the NDA and sNDA review period for the above two drugs.


    Some analysts pointed out that the postponement of the review of the above-mentioned JAK inhibitors indicates that the FDA will strictly review all drugs in this category.


    At present, the drug labels of Olumiant, Xeljanz, and Rinvoq all have a black box warning about the risk of serious infection, blood clots, and cancer.


    As the FDA considers taking action on Xeljanz's existing indications, the agency is now also carefully studying pending applications for the entire JAK class of drugs.


    Although delaying the review of JAK inhibitors is a setback for the aforementioned companies, it also means that competition between Sanofi and Regeneron's monoclonal anti-inflammatory drug Dupixent is reduced or delayed.


    AD is currently Dupixent's largest indication and a "significant growth driver.


    Among the three JAK inhibitors that have been postponed for review, Xeljanz has the highest revenue in 2020, reaching $2.


    Reference source:

    1.


    2.


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.